BioCentury
ARTICLE | Politics & Policy

China rare disease list could promote R&D, regulatory filings

May 25, 2018 11:20 PM UTC

Five Chinese government agencies, including the State Drug Administration and the National Health Commission, published a national list of 121 qualified rare diseases to support diagnosis and treatment of such conditions in a move that could spur R&D and regulatory submissions for rare disease therapies.

This is the first time China has recognized rare diseases on a national level, James Xue told BioCentury. Xue is founder, chairman and CEO of Canbridge Life Sciences Ltd. (Beijing, China) and previously served as first China general manager of rare diseases pioneer Genzyme Corp., which is now part of Sanofi (Euronext:SAN; NYSE:SNY)...

BCIQ Company Profiles

Canbridge Pharmaceuticals Inc.